Everest Medicines Ltd. ( (HK:1952) ) has provided an update.
Everest Medicines Limited announced that it has received approval from the Hong Kong Stock Exchange to dis-apply certain listing rules, resulting in the removal of the ‘B’ marker from its stock short name. This change reflects the company’s compliance with the market capitalization and revenue requirements, signifying its growth and stability in the biotechnology sector.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biotechnology company that was listed on the Main Board of the Stock Exchange of Hong Kong in October 2020. The company focuses on developing and commercializing transformative pharmaceutical products to address critical unmet medical needs in Asia and other emerging markets.
YTD Price Performance: -2.69%
Average Trading Volume: 5,232,793
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.38B
For detailed information about 1952 stock, go to TipRanks’ Stock Analysis page.